Company

Company

Humab strives to improve health and well-being

for the humankind through genome engineering.



  • We develop SynTheseTM, a transgenic antibody platform, by utilizing our genome engineering technology.
  • SynTheseTM is a powerful tool that can produce human monoclonal antibodies.
  • Humab will lead development of new antibody drugs via collaboration or co-development with global pharmaceutical companies.



  • Antibody drugs have evolved from humanized antibodies to fully-human antibodies.
  • Two base platform technologies enable the development of fully-human antibodies: phage display and transgenic mouse platforms.
  • About 75% of all the fully-human antibodies approved by FDA through 2017 were developed based on the transgenic platform. We believe it is the most effective technology for producing fully-human antibodies.